Table 1 Patients’ demographic characteristics and immunosuppression regimen
All patients (n = 475) | Survivors (n = 428) | Non-survivors (n = 47) | p-value | |
|---|---|---|---|---|
Age (year) | 47 (37–56) | 46 (36–55) | 54 (44–62) | < 0.001 |
Sex | 0.095 | |||
Male | 290 (61.1) | 256 (59.8) | 34 (72.3) | |
Female | 185 (38.9) | 172 (40.2) | 13 (27.7) | |
Post-transplant follow-up (months) | 76 (41–113) | 80 (41–135) | 64 (44–100) | 0.304 |
Etiology of CKD | ||||
Hypertensive nephropathy | 49 (10.3) | 44 (10.3) | 5 (10.6) | 0.55 |
Diabetic nephropathy | 49 (10.3) | 38 (8.9) | 11 (23.4) | 0.005 |
Chronic glomerulonephritis | 72 (15.2) | 67 (15.7) | 5 (10.6) | 0.48 |
CAKUT | 76 (16) | 73 (17.1) | 3 (6.4) | 0.037 |
Other | 29 (30.8) | 25 (5.8) | 4 (8.5) | 0.32 |
Unknown | 200 (42.1) | 181 (42.3) | 19 (40.4) | 0.92 |
Comorbid diseases | ||||
Pre-existing lung disease | 33 (6.9) | 30 (7) | 3 (6.4) | 0.583 |
Previous heart disease | 70 (14.7) | 55 (12.9) | 15 (31.9) | 0.001 |
Chronic hypertension | 351 (73.9) | 314 (73.4) | 37 (78.7) | 0.537 |
Post-transplant diabetes mellitus | 89 (18.9) | 72 (16.9) | 17 (36.2) | 0.002 |
Malignancy | 6 (1.2) | 5 (1.2) | 1 (2.1) | 0.897 |
Type of donor | ||||
Living | 395 (83.2) | 356 (83.2) | 39 (83) | 0.972 |
Deceased | 80 (16.8) | 72 (16.8) | 8 (17) | |
Induction therapy | ||||
ATLG | 272 (57.3) | 240 (56.1) | 32 (68.1) | 0.545 |
Basiliximab | 32 (6.7) | 32 (7.5) | 0 | < 0.001 |
Posttransplant complications | ||||
Allograft rejection | 53 (11.2) | 46 (10.7) | 7 (14.9) | 0.54 |
BK virus nephropathy | 7 (1.5) | 7 (1.6) | 0 | |
CMV viremia | 4 (0.8) | 4 (0.9) | 0 | |
Maintenance immunosuppression at admission | ||||
Tacrolimus | 404 (85.1) | 363 (84.8) | 41 (87.2) | 0.823 |
Cyclosporine A | 38 (8) | 37 (8.6) | 1(2.1) | 0.09 |
Everolimus | 40 (8.4) | 35 (8.2) | 5 (10.6) | 0.36 |
Sirolimus | 6 (12.6) | 6 (1.4) | 0 | 0.533 |
Mycophenolate derivatives | 430 (90.5) | 388 (90.6) | 42 (89.4) | 0.466 |
Azathioprine | 19 (4) | 18 (4.2) | 1 (2.1) | 0.421 |
Steroids | 467 (98.3) | 422 (98.6) | 45 (95.7) | 0.182 |